A meta analysis of pancreatic microarray datasets yields new targets as cancer genes and biomarkers

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Goonesekere, Nalin C W ^a   Wang, Xiaosheng ^b   Ludwig, Lindsey ^a   Guda, Chittibabu ^b,c  

^a UNIVERSITY OF NORTHERN IOWA   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROTEIN KINASE; GENETIC MARKER; TUMOR MARKER;

ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DISEASE ACTIVITY; DNA METHYLATION; GENE; GENE FUNCTION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; INFLAMMATION; MICROARRAY ANALYSIS; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MULTIGENE FAMILY; ONCOGENE; PANCREAS CANCER; PROTEIN KINASE GENE; SIGNAL TRANSDUCTION; UPREGULATION; CPG ISLAND; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETIC MARKER; GENETICS; META ANALYSIS; PANCREAS TUMOR; PROMOTER REGION; AHNAK2 GENE; CDH3 GENE; CEACAM5 GENE; CEACAM6 GENE; CLDN18 GENE; COL11A1 GENE; COL1A1 GENE; COL1A2 GENE; CTHRC1 GENE; CTSE GENE; DATA BASE; EPPK1 GENE; FN1 GENE; GENETIC IDENTIFICATION; GPRC5A GENE; IGHG3 GENE; KRT19 GENE; METASTASIS; MMP11 GENE; MUC4 GENE; OLFM4 GENE; TUMOR GENE;

CPG ISLANDS; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GENETIC MARKERS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PANCREATIC NEOPLASMS; PROMOTER REGIONS, GENETIC; UP-REGULATION;

EID: 84899680444     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093046.t001     Document Type: Article

References (120)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
2. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, et al. (2011) SEER Cancer Statistics Review, 1975-2009.
3. Chakraborty S, Baine MJ, Sasson AR, Batra SK (2011) Current status of molecular markers for early detection of sporadic pancreatic cancer. Biochim Biophys Acta 1815: 44-64.
4. Stratton MR (2011) Exploring the genomes of cancer cells: progress and promise. Science 331: 1553-1558.
5. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, et al. (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321: 1801-1806.
6. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, et al. (2007) Patterns of somatic mutation in human cancer genomes. Nature 446: 153-158. (Pubitemid 46398669)
7. Schinzel AC, Hahn WC (2008) Oncogenic transformation and experimental models of human cancer. Front Biosci 13: 71-84. (Pubitemid 351594764)
8. Beerenwinkel N, Antal T, Dingli D, Traulsen A, Kinzler KW, et al. (2007) Genetic progression and the waiting time to cancer. PLoS Comput Biol 3: e225.
9. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, et al. (2004) A census of human cancer genes. Nat Rev Cancer 4: 177-183. (Pubitemid 38337497)
10. Touw IP, Erkeland SJ (2007) Retroviral insertion mutagenesis in mice as a comparative oncogenomics tool to identify disease genes in human leukemia. Mol Ther 15: 1319. (Pubitemid 46043644)
11. Stuart D, Sellers WR (2009) Linking somatic genetic alterations in cancer to therapeutics. Curr Opin Cell Biol 21: 304-310.
12. Ko JM, Fisher DE (2011) A new era: melanoma genetics and therapeutics. J Pathol 223: 241-250.
13. Marson CM (2009) Histone deacetylase inhibitors: design, structure-activity relationships and therapeutic implications for cancer. Anticancer Agents Med Chem 9: 661-692.
14. Bunger S, Laubert T, Roblick UJ, Habermann JK (2011) Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview. J Cancer Res Clin Oncol 137: 375-389.
15. Xu Qao Advances in early diagnosis and therapy of pancreatic cancer.
16. Yachida S, Jones S, Bozic I, Antal T, Leary R, et al. (2010) Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467: 1114-1117.
17. Goonetilleke KS, Siriwardena AK (2007) Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 33: 266-270. (Pubitemid 46488663)
18. Ramasamy A, Mondry A, Holmes CC, Altman DG (2008) Key issues in conducting a meta-analysis of gene expression microarray datasets. PLoS Med 5: e184.
19. Irizarry RA, Warren D, Spencer F, Kim IF, Biswal S, et al. (2005) Multiplelaboratory comparison of microarray platforms. Nat Methods 2: 345-350.
20. Grutzmann R, Boriss H, Ammerpohl O, Luttges J, Kalthoff H, et al. (2005) Meta-analysis of microarray data on pancreatic cancer defines a set of commonly dysregulated genes. Oncogene 24: 5079-5088. (Pubitemid 41129085)
21. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, et al. (2004) ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6: 1-6. (Pubitemid 38391943)
22. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, et al. (2007) Oncomine 3. 0: Genes, Pathways, and Networks in a Collection of. 18,000 Cancer Gene Expression Profiles. NEO. 9: 166-180
23. Smid M, Dorssers LCJ, Jenster G (2003) Venn Mapping: clustering of heterologous microarray data based on the number of co-occurring differentially expressed genes. Bioinformatics 19: 2065-2071. (Pubitemid 37408157)
24. Hong F, Breitling R, McEntee CW, Wittner BS, Nemhauser JL, et al. (2006) RankProd: a bioconductor package for detecting differentially expressed genes in meta-analysis. Bioinformatics 22: 2825-2827. (Pubitemid 44742407)
25. Laing E, Smith CP (2010) RankProdIt: A web-interactive Rank Products analysis tool. BMC Res Notes 3: 221.
26. Breitling R, Armengaud P, Amtmann A, Herzyk P (2004) Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments. FEBS Lett 573: 83-92. (Pubitemid 39141040)
27. Dudley JT, Tibshirani R, Deshpande T, Butte AJ (2009) Disease signatures are robust across tissues and experiments. Mol Syst Biol 5: 307.
28. Hong F, Breitling R (2008) A comparison of meta-analysis methods for detecting differentially expressed genes in microarray experiments. Bioinformatics 24: 374-382. (Pubitemid 351189013)
29. Yonezawa S, Higashi M, Yamada N, Yokoyama S, Kitamoto S, et al. (2011) Mucins in human neoplasms: clinical pathology, gene expression and diagnostic application. Pathol Int 61: 697-716.
30. Blumenthal RD, Leon E, Hansen HJ, Goldenberg DM (2007) Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers. BMC Cancer 7: 2.
31. Jiang H, Hu H, Tong X, Jiang Q, Zhu H, et al. (2012) Calcium-binding protein S100P and cancer: mechanisms and clinical relevance. J Cancer Res Clin Oncol 138: 1-9.
32. Tanaka M, Shibahara J, Fukushima N, Shinozaki A, Umeda M, et al. (2011) Claudin-18 is an early-stage marker of pancreatic carcinogenesis. J Histochem Cytochem 59: 942-952.
33. Jain R, Fischer S, Serra S, Chetty R (2010) The use of Cytokeratin 19 (CK19) immunohistochemistry in lesions of the pancreas, gastrointestinal tract, and liver. Appl Immunohistochem Mol Morphol 18: 9-15.
34. Provenzano PP, Eliceiri KW, Campbell JM, Inman DR, White JG, et al. (2006) Collagen reorganization at the tumor-stromal interface facilitates local invasion. BMC Med 4: 38.
35. Magrane M, Consortium U (2011) UniProt Knowledgebase: a hub of integrated protein data. Database (Oxford) 2011: bar009.
36. Komuro A, Masuda Y, Kobayashi K, Babbitt R, Gunel M, et al. (2004) The AHNAKs are a class of giant propeller-like proteins that associate with calcium channel proteins of cardiomyocytes and other cells. Proc Natl Acad Sci U S A 101: 4053-4058. (Pubitemid 38405882)
37. Haase H, Alvarez J, Petzhold D, Doller A, Behlke J, et al. (2005) Ahnak is critical for cardiac Ca(V) 1. 2 calcium channel function and its beta-adrenergic regulation. FASEB J 19: 1969-1977. (Pubitemid 41759742)
38. Marg A, Haase H, Neumann T, Kouno M, Morano I (2010) AHNAK1 and AHNAK2 are costameric proteins: AHNAK1 affects transverse skeletal muscle fiber stiffness. Biochem Biophys Res Commun 401: 143-148.
39. Shankar J, Messenberg A, Chan J, Underhill TM, Foster LJ, et al. (2010) Pseudopodial actin dynamics control epithelial-mesenchymal transition in metastatic cancer cells. Cancer Res 70: 3780-3790.
40. Beachy PA, Karhadkar SS, Berman DM (2004) Tissue repair and stem cell renewal in carcinogenesis. Nature 432: 324-331. (Pubitemid 39551660)
41. Tang L, Dai DL, Su M, Martinka M, Li G, et al. (2006) Aberrant expression of collagen triple helix repeat containing 1 in human solid cancers. Clin Cancer Res 12: 3716-3722. (Pubitemid 44000252)
42. Turashvili G, Bouchal J, Baumforth K, Wei W, Dziechciarkova M, et al. (2007) Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer 7: 55.
43. Chiu ST, Hsieh FJ, Chen SW, Chen CL, Shu HF, et al. (2005) Clinicopathologic correlation of up-regulated genes identified using cDNA microarray and real-time reverse transcription-PCR in human colorectal cancer. Cancer Epidemiol Biomarkers Prev 14: 437-443.
44. Wang P, Wang YC, Chen XY, Shen ZY, Cao H, et al. (2012) CTHRC1 is upregulated by promoter demethylation and transforming growth factor-beta1 and may be associated with metastasis in human gastric cancer. Cancer Sci
45. Ishikawa K, Sumiyoshi H, Matsuo N, Takeo N, Goto M, et al. (2010) Epiplakin accelerates the lateral organization of keratin filaments during wound healing. J Dermatol Sci 60: 95-104.
46. Kim R, Emi M, Tanabe K (2006) Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity. Immunology 119: 254-264. (Pubitemid 44401644)
47. Leivonen SK, Kahari VM (2007) Transforming growth factor-beta signaling in cancer invasion and metastasis. Int J Cancer 121: 2119-2124.
48. Ganapathy V, Ge R, Grazioli A, Xie W, Banach-Petrosky W, et al. (2010) Targeting the Transforming Growth Factor-beta pathway inhibits human basal-like breast cancer metastasis. Mol Cancer 9: 122.
49. Ray DM, Myers PH, Painter JT, Hoenerhoff MJ, Olden K, et al. (2012) Inhibition of transforming growth factor-beta-activated kinase-1 blocks cancer cell adhesion, invasion, and metastasis. Br J Cancer 107: 129-136.
50. Melisi D, Ishiyama S, Sclabas GM, Fleming JB, Xia Q, et al. (2008) LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther 7: 829-840. (Pubitemid 351551036)
51. Korpal M, Yan J, Lu X, Xu S, Lerit DA, et al. (2009) Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat Med 15: 960-966.
52. May MJ, Ghosh S (1998) Signal transduction through NF-kappa B. Immunol Today 19: 80-88.
53. Karin M, Staudt L (2010) NF-[kappa] B: a network hub controlling immunity, inflammation, and cancer:. Cold Spring Harbor, N. Y.: Cold Spring Harbor Laboratory Press. 271 p.
54. Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, et al. (2013) Inflammationinduced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer 13: 759-771.
55. Lesina M, Kurkowski MU, Ludes K, Rose-John S, Treiber M, et al. (2011) Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 19: 456-469.
56. Yoon J, Cho SJ, Ko YS, Park J, Shin DH, et al. (2013) A synergistic interaction between transcription factors nuclear factor-kappaB and signal transducers and activators of transcription 3 promotes gastric cancer cell migration and invasion. BMC Gastroenterol 13: 29.
57. Van Laere SJ, Van der Auwera I, Van den Eynden GG, Elst HJ, Weyler J, et al. (2006) Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription- PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding. Clin Cancer Res 12: 3249-3256.
58. Song JK, Jo MR, Park MH, Song HS, An BJ, et al. (2012) Cell growth inhibition and induction of apoptosis by snake venom toxin in ovarian cancer cell via inactivation of nuclear factor kappaB and signal transducer and activator of transcription 3. Arch Pharm Res 35: 867-876.
59. Peant B, Diallo JS, Lessard L, Delvoye N, Le Page C, et al. (2007) Regulation of IkappaB kinase epsilon expression by the androgen receptor and the nuclear factor-kappaB transcription factor in prostate cancer. Mol Cancer Res 5: 87-94.
60. Lessard L, Begin LR, Gleave ME, Mes-Masson AM, Saad F (2005) Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study. Br J Cancer 93: 1019-1023. (Pubitemid 41548396)
61. Yuzhalin AE, Kutikhin AG (2012) Inherited variations in the SOD and GPX gene families and cancer risk. Free Radic Res 46: 581-599.
62. Erdem O, Eken A, Akay C, Arsova-Sarafinovska Z, Matevska N, et al. (2012) Association of GPX1 polymorphism, GPX activity and prostate cancer risk. Hum Exp Toxicol 31: 24-31.
63. Cox DG, Tamimi RM, Hunter DJ (2006) Gene x Gene interaction between MnSOD and GPX-1 and breast cancer risk: a nested case-control study. BMC Cancer 6: 217.
64. Liu J, Du J, Zhang Y, Sun W, Smith BJ, et al. (2006) Suppression of the malignant phenotype in pancreatic cancer by overexpression of phospholipid hydroperoxide glutathione peroxidase. Hum Gene Ther 17: 105-116. (Pubitemid 43100519)
65. Enserink JM, Kolodner RD (2010) An overview of Cdk1-controlled targets and processes. Cell Div 5: 11.
66. Zhu F, Shi Z, Qin C, Tao L, Liu X, et al. (2012) Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res 40: D1128-36.
67. Schade AE, Schieven GL, Townsend R, Jankowska AM, Susulic V, et al. (2008) Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits Tcell activation and proliferation. Blood 111: 1366-1377. (Pubitemid 351213423)
68. Lee KC, Ouwehand I, Giannini AL, Thomas NS, Dibb NJ, et al. (2010) Lck is a key target of imatinib and dasatinib in T-cell activation. Leukemia 24: 896-900.
69. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, et al. (1991) Identification of the hepatocyte growth factor receptor as the c-met protooncogene product. Science 251: 802-804. (Pubitemid 21926175)
70. Liu X, Newton RC, Scherle PA (2010) Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol Med 16: 37-45.
71. Underiner TL, Herbertz T, Miknyoczki SJ (2010) Discovery of small molecule c-Met inhibitors: Evolution and profiles of clinical candidates. Anticancer Agents Med Chem 10: 7-27.
72. Vijay Kumar D, Hoarau C, Bursavich M, Slattum P, Gerrish D, et al. (2012) Lead optimization of purine based orally bioavailable Mps1 (TTK) inhibitors. Bioorg Med Chem Lett 22: 4377-4385.
73. Santaguida S, Tighe A, D'Alise AM, Taylor SS, Musacchio A (2010) Dissecting the role of MPS1 in chromosome biorientation and the spindle checkpoint through the small molecule inhibitor reversine. J Cell Biol 190: 73-87.
74. Caldarelli M, Angiolini M, Disingrini T, Donati D, Guanci M, et al. (2011) Synthesis and SAR of new pyrazolo[4,3-h]quinazoline-3-carboxamide derivatives as potent and selective MPS1 kinase inhibitors. Bioorg Med Chem Lett 21: 4507-4511.
75. Kwiatkowski N, Jelluma N, Filippakopoulos P, Soundararajan M, Manak MS, et al. (2010) Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function. Nat Chem Biol 6: 359-368.
76. Choi YL, Bocanegra M, Kwon MJ, Shin YK, Nam SJ, et al. (2010) LYN is a mediator of epithelial-mesenchymal transition and a target of dasatinib in breast cancer. Cancer Res 70: 2296-2306.
77. Williams BR, Amon A (2009) Aneuploidy: cancer's fatal flaw? Cancer Res 69: 5289-5291.
78. King RW (2008) When 2+2 = 5: the origins and fates of aneuploid and tetraploid cells. Biochim Biophys Acta 1786: 4-14.
79. Ito H, Gardner-Thorpe J, Zinner MJ, Ashley SW, Whang EE (2003) Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness. Surgery 134: 221-226. (Pubitemid 37070342)
80. Levitzki A, Mishani E (2006) Tyrphostins and other tyrosine kinase inhibitors. Annu Rev Biochem 75: 93-109. (Pubitemid 44118027)
81. Hong SM, Park JY, Hruban RH, Goggins M (2011) Molecular signatures of pancreatic cancer. Arch Pathol Lab Med 135: 716-727.
82. Tan AC, Jimeno A, Lin SH, Wheelhouse J, Chan F, et al. (2009) Characterizing DNA methylation patterns in pancreatic cancer genome. Mol Oncol 3: 425-438.
83. Zhu Y, Zhang JJ, Zhu R, Zhu Y, Liang WB, et al. (2011) The increase in the expression and hypomethylation of MUC4 gene with the progression of pancreatic ductal adenocarcinoma. Med Oncol 28 Suppl 1: S175-84.
84. Matsubayashi H, Sato N, Fukushima N, Yeo CJ, Walter KM, et al. (2003) Methylation of cyclin D2 is observed frequently in pancreatic cancer but is also an age-related phenomenon in gastrointestinal tissues. Clin Cancer Res 9: 1446-1452. (Pubitemid 36418400)
85. Baylin SB, Jones PA (2011) A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer 11: 726-734.
86. Maier T, Guell M, Serrano L. (2009) Correlation of mRNA and protein in complex biological samples. FEBS Lett 583: 3966-3973.
87. Cecconi D, Palmieri M, Donadelli M (2011) Proteomics in pancreatic cancer research. Proteomics 11: 816-828.
88. Sun C, Rosendahl AH, Ansari D, Andersson R (2011) Proteome-based biomarkers in pancreatic cancer. World J Gastroenterol 17: 4845-4852.
89. Bachet JB, Marechal R, Demetter P, Bonnetain F, Cros J, et al. (2013) S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma. Eur J Cancer 49: 2643-2653.
90. Marenholz I, Heizmann CW, Fritz G (2004) S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun 322: 1111-1122. (Pubitemid 39164640)
91. Nakata K, Nagai E, Ohuchida K, Hayashi A, Miyasaka Y, et al. (2010) S100P is a novel marker to identify intraductal papillary mucinous neoplasms. Hum Pathol 41: 824-831.
92. Dim DC, Jiang F, Qiu Q, Li T, Darwin P, et al. (2011) The usefulness of S100P, mesothelin, fascin, prostate stem cell antigen, and 14-3-3 sigma in diagnosing pancreatic adenocarcinoma in cytological specimens obtained by endoscopic ultrasound guided fine-needle aspiration. Diagn Cytopathol
93. Goodell CA, Belisle JA, Gubbels JA, Migneault M, Rancourt C, et al. (2009) Characterization of the tumor marker muc16 (ca125) expressed by murine ovarian tumor cell lines and identification of a panel of cross-reactive monoclonal antibodies. J Ovarian Res 2: 8.
94. Kessenbrock K, Plaks V, Werb Z (2010) Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141: 52-67.
95. Roy R, Yang J, Moses MA (2009) Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 27: 5287-5297.
96. Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442-454.
97. Hua H, Li M, Luo T, Yin Y, Jiang Y (2011) Matrix metalloproteinases in tumorigenesis: an evolving paradigm. Cell Mol Life Sci 68: 3853-3868.
98. Singh P, Srinivasan R, Wig JD (2011) Major molecular markers in pancreatic ductal adenocarcinoma and their roles in screening, diagnosis, prognosis, and treatment. Pancreas 40: 644-652.
99. Pryczynicz A, Guzinska-Ustymowicz K, Dymicka-Piekarska V, Czyzewska J, Kemona A (2007) Expression of matrix metalloproteinase 9 in pancreatic ductal carcinoma is associated with tumor metastasis formation. Folia Histochem Cytobiol 45: 37-40. (Pubitemid 46416518)
100. Yokoyama M, Ochi K, Ichimura M, Mizushima T, Shinji T, et al. (2002) Matrix metalloproteinase-2 in pancreatic juice for diagnosis of pancreatic cancer. Pancreas 24: 344-347. (Pubitemid 34441914)
101. Jones LE, Humphreys MJ, Campbell F, Neoptolemos JP, Boyd MT (2004) Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: increased expression of matrix metalloproteinase- 7 predicts poor survival. Clin Cancer Res 10: 2832-2845 (Pubitemid 38509163)
102. Motrescu ER, Rio MC (2008) Cancer cells, adipocytes and matrix metalloproteinase 11: a vicious tumor progression cycle. Biol Chem 389: 1037-1041.
103. Kren L, Goncharuk VN, Krenova Z, Stratil D, Hermanova M, et al. (2006) Expression of matrix metalloproteinases 3, 10 and 11 (stromelysins 1, 2 and 3) and matrix metalloproteinase 7 (matrilysin) by cancer cells in non-small cell lung neoplasms. Clinicopathologic studies. Cesk Patol 42: 16-19.
104. Wasenius VM, Hemmer S, Kettunen E, Knuutila S, Franssila K, et al. (2003) Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study. Clin Cancer Res 9: 68-75. (Pubitemid 36109717)
105. Mellick AS, Blackmore D, Weinstein SR, Griffiths LR (2003) An assessment of MMP and TIMP gene expression in cell lines and stroma - tumour differences in microdissected breast cancer biopsies. Tumour Biol 24: 258-270. (Pubitemid 38316496)
106. Bauvois B (2012) New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim Biophys Acta 1825: 29-36.
107. Burrell RA, McGranahan N, Bartek J, Swanton C (2013) The causes and consequences of genetic heterogeneity in cancer evolution. Nature 501: 338-345.
108. Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, et al. (2010) The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467: 1109-1113.
109. Zahreddine H, Borden KL (2013) Mechanisms and insights into drug resistance in cancer. Front Pharmacol 4: 28.
110. Sato N, Fukushima N, Maitra A, Matsubayashi H, Yeo CJ, et al. (2003) Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res 63: 3735-3742. (Pubitemid 36793060)
111. Fitzgerald M, Oshiro M, Holtan N, Krager K, Cullen JJ, et al. (2003) Human pancreatic carcinoma cells activate maspin expression through loss of epigenetic control. Neoplasia 5: 427-436. (Pubitemid 37475651)
112. Ohike N, Maass N, Mundhenke C, Biallek M, Zhang M, et al. (2003) Clinicopathological significance and molecular regulation of maspin expression in ductal adenocarcinoma of the pancreas. Cancer Lett 199: 193-200. (Pubitemid 37297712)
113. Kwon MJ, Kim SH, Jeong HM, Jung HS, Kim SS, et al. (2011) Claudin-4 overexpression is associated with epigenetic derepression in gastric carcinoma. Lab Invest 91: 1652-1667.
114. Shiba-Ishii A, Noguchi M (2012) Aberrant stratifin overexpression is regulated by tumor-associated CpG demethylation in lung adenocarcinoma. Am J Pathol 180: 1653-1662.
115. Vestergaard EM, Nexo E, Torring N, Borre M, Orntoft TF, et al. (2010) Promoter hypomethylation and upregulation of trefoil factors in prostate cancer. Int J Cancer 127: 1857-1865.
116. Rosty C, Ueki T, Argani P, Jansen M, Yeo CJ, et al. (2002) Overexpression of S100A4 in pancreatic ductal adenocarcinomas is associated with poor differentiation and DNA hypomethylation. Am J Pathol 160: 45-50. (Pubitemid 34052264)
117. Nelson HH, Almquist LM, LaRocca JL, Plaza SL, Lambert-Messerlian GM, et al. (2011) The relationship between tumor MSLN methylation and serum mesothelin (SMRP) in mesothelioma. Epigenetics 6: 1029-1034.
118. Li Y, Meng G, Guo QN (2008) Changes in genomic imprinting and gene expression associated with transformation in a model of human osteosarcoma. Exp Mol Pathol 84: 234-239.
119. Dimberg J, Strom K, Lofgren S, Zar N, Lindh M, et al. (2012) DNA promoter methylation status and protein expression of interleukin-8 in human colorectal adenocarcinomas. Int J Colorectal Dis 27: 709-714.
120. Komatsu Y, Waku T, Iwasaki N, Ono W, Yamaguchi C, et al. (2012) Global analysis of DNA methylation in early-stage liver fibrosis. BMC Med Genomics 5: 5. comparative oncogenomics tool to identify disease genes in human leukemia. Mol Ther 15: 13-19.